ADHD biotech Neos Therapeutics sets terms for $60 million IPO

Shutterstock photo

Neos Therapeutics, a late stage biotech developing extended release formulations of ADHD therapies, announced terms for its IPO on Monday.

The Grand Prairie, TX-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, it would command a fully diluted market value of $220 million.

Neos Therapeutics, which was founded in 1994, plans to list on the NASDAQ under the symbol NEOS. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of July 20, 2015.

The article ADHD biotech Neos Therapeutics sets terms for $60 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
Referenced Symbols: NEOS

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?